Abstract
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a rare, heterogeneous, life-threatening, autoimmune condition. This study aimed to evaluate the cost-utility of avacopan in combination with rituximab or cyclophosphamide compared with glucocorticoids (GC) and cyclophosphamide or rituximab for the treatment of severe, active AAV from the Spanish National Health System perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
